Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus reuteri CCFM1132
- Development stage
- Unknown
- Lead developer
- Jiangnan University
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus reuteri CCFM1132 is a specific probiotic strain of the species Lactobacillus reuteri (also known as Limosilactobacillus reuteri). It has been studied for its ability to modulate gut microbiota and exert beneficial effects in several disease models. Mechanistically, it lowers serum uric acid by suppressing xanthine oxidase activity and increasing the abundance of short-chain fatty acid (SCFA) producers in the gut. This leads to increased SCFA production, which is negatively correlated with uric acid levels and xanthine oxidase activity. The strain also improves liver and renal function markers in clinical studies. Preclinical research indicates additional benefits such as reducing skin stratum corneum thickening (potentially relevant for psoriasis), lowering blood creatinine, triglycerides, alkaline phosphatase activity, and upregulating intestinal uric acid transporter ABCG2 expression[6][7][10]. It is primarily developed as a functional probiotic for hyperuricemia/gout relief but may have broader applications including skin health.
- Other names
- 罗伊氏乳杆菌CCFM1132Limosilactobacillus reuteri CCFM1132
02
Targets
ABCG2 (Breast cancer resistance protein)XO (Xanthine Oxidoreductase)
Beyond the preview
Go deeper on lactobacillus reuteri CCFM1132.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus reuteri CCFM1132.